MARKET

ISR

ISR

ISORAY
AMEX

Real-time Quotes | Nasdaq Last Sale

0.3565
+0.0134
+3.91%
Opening 15:18 01/27 EST
OPEN
0.3431
PREV CLOSE
0.3431
HIGH
0.3612
LOW
0.3431
VOLUME
461.35K
TURNOVER
--
52 WEEK HIGH
2.400
52 WEEK LOW
0.3250
MARKET CAP
50.59M
P/E (TTM)
-8.9573
1D
5D
1M
3M
1Y
5Y
Isoray To Announce Second Quarter Fiscal 2022 Financial Results on February 8, 2022
Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PTRICHLAND, Wash., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will ho...
GlobeNewswire · 1d ago
BRIEF-Isoray Inc - Will Manufacture And Supply Cesium-131 Brachytherapy Seeds To Gt Med Tech Rather Than Gammatiles
reuters.com · 11/23/2021 21:12
IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com · 11/10/2021 23:45
BRIEF-Isoray Posts Q1 Loss Per Share Of $0.02
reuters.com · 11/10/2021 22:13
IsoRay Q1 EPS $(0.02) Misses $(0.01) Estimate, Sales $2.56M Beat $2.49M Estimate
IsoRay (AMEX:ISR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 100 percent decrease over losses of $(0.01) per share from the same period
Benzinga · 11/10/2021 21:51
IsoRay EPS misses by $0.01, beats on revenue
IsoRay (NYSE:ISR): FQ1 GAAP EPS of -$0.02 misses by $0.01. Revenue of $2.56M (+7.6% Y/Y) beats by $0.06M. Press Release Isoray CEO Lori Woods said, “We are encouraged by the prospects for
Seekingalpha · 11/10/2021 21:09
-- Earnings Flash (ISR) ISORAY Posts Q1 Revenue $2.56M, vs. Street Est of $2.5M
MT Newswires · 11/10/2021 16:26
-- Earnings Flash (ISR) ISORAY Reports Q1 Loss $-0.02, vs. Street Est of $-0.01
MT Newswires · 11/10/2021 16:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ISR. Analyze the recent business situations of ISORAY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ISR stock price target is 1.633 with a high estimate of 2.000 and a low estimate of 1.250.
High2.000
Average1.633
Low1.250
Current 0.3562
EPS
Actual
Estimate
-0.02-0.01-0.01-0.00
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 29
Institutional Holdings: 3.97M
% Owned: 2.80%
Shares Outstanding: 141.92M
TypeInstitutionsShares
Increased
3
180.54K
New
3
75.96K
Decreased
3
935.88K
Sold Out
6
261.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.63%
Healthcare Equipment & Supplies
-0.73%
Key Executives
Non-Executive Chairman/Independent Director
Michael Mccormick
Chief Executive Officer/Director
Lori Woods
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Controller/Secretary
Mark Austin
Chief Financial Officer
Jonathan Hunt
Chief Operating Officer/Vice President/Director of Human Resources
Jennifer Streeter
Other
William Cavanagh
Independent Director
Alan Hoffmann
Independent Director
Philip Vitale
No Data
About ISR
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Cesium-131 seed is classified as a Class II device.

Webull offers kinds of IsoRay, Inc. stock information, including AMEX:ISR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISR stock methods without spending real money on the virtual paper trading platform.